

# Matthew P. Cheng

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4725781/publications.pdf>

Version: 2024-02-01

120  
papers

4,650  
citations

218381

26  
h-index

118652

62  
g-index

130  
all docs

130  
docs citations

130  
times ranked

9581  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 517-525.	13.9	1,081
2	Diagnostic Testing for Severe Acute Respiratory Syndrome–Related Coronavirus 2. <i>Annals of Internal Medicine</i> , 2020, 172, 726-734.	2.0	517
3	Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19. <i>Annals of Internal Medicine</i> , 2020, 173, 623-631.	2.0	444
4	Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2021, 16, e0252617.	1.1	185
5	SeroTracker: a global SARS-CoV-2 seroprevalence dashboard. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e75-e76.	4.6	175
6	Blood Culture Results Before and After Antimicrobial Administration in Patients With Severe Manifestations of Sepsis. <i>Annals of Internal Medicine</i> , 2019, 171, 547.	2.0	125
7	Serodiagnostics for Severe Acute Respiratory Syndrome–Related Coronavirus 2. <i>Annals of Internal Medicine</i> , 2020, 173, 450-460.	2.0	124
8	Prognostic factors in 264 adults with invasive <i>Scedosporium</i> spp. and <i>Lomentospora prolificans</i> infection reported in the literature and FungiScope. <i>Critical Reviews in Microbiology</i> , 2019, 45, 1-21.	2.7	106
9	Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. <i>Cmaj</i> , 2022, 194, E242-E251.	0.9	103
10	Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2018, 2, 2159-2175.	2.5	89
11	Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non–Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1037-1042.	0.5	83
12	Microbial Biofilms in Pulmonary and Critical Care Diseases. <i>Annals of the American Thoracic Society</i> , 2016, 13, 1615-1623.	1.5	74
13	Risk of Active Tuberculosis in Patients with Cancer: A Systematic Review and Meta-Analysis. <i>Clinical Infectious Diseases</i> , 2017, 64, ciw838.	2.9	73
14	Staphylococcus aureus bacteraemia mortality: a systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1076-1084.	2.8	73
15	Diagnostic accuracy of serum (1-3)- $\beta$ -D-glucan for <i>Pneumocystis jirovecii</i> pneumonia: a systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1137-1143.	2.8	72
16	A cell-free DNA metagenomic sequencing assay that integrates the host injury response to infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 18738-18744.	3.3	58
17	Characteristics and outcomes of patients with COVID-19 admitted to hospital and intensive care in the first phase of the pandemic in Canada: a national cohort study. <i>CMAJ Open</i> , 2021, 9, E181-E188.	1.1	49
18	A case report of a deep surgical site infection with <i>Terrisporobacter glycolicus</i> /T. Mayombei and review of the literature. <i>BMC Infectious Diseases</i> , 2016, 16, 529.	1.3	46

#	ARTICLE	IF	CITATIONS
19	Post-vaccination myositis and myocarditis in a previously healthy male. <i>Allergy, Asthma and Clinical Immunology</i> , 2016, 12, 6.	0.9	40
20	Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa500.	0.4	38
21	Back to the Future: Penicillin-Susceptible <i>Staphylococcus aureus</i> . <i>American Journal of Medicine</i> , 2016, 129, 1331-1333.	0.6	36
22	Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic. <i>Cmaj</i> , 2020, 192, E405-E407.	0.9	36
23	Adjunctive Daptomycin in the Treatment of Methicillin-susceptible <i>Staphylococcus aureus</i> Bacteremia: A Randomized, Controlled Trial. <i>Clinical Infectious Diseases</i> , 2021, 72, e196-e203.	2.9	34
24	Galectin-3 enhances neutrophil motility and extravasation into the airways during <i>Aspergillus fumigatus</i> infection. <i>PLoS Pathogens</i> , 2020, 16, e1008741.	2.1	33
25	Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab220.	0.4	33
26	Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn). <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3315-3327.	1.3	30
27	Adapting Serosurveys for the SARS-CoV-2 Vaccine Era. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab632.	0.4	30
28	Visual Hallucinations Associated with High Posaconazole Concentrations in Serum. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1170-1171.	1.4	28
29	<i>Pneumocystis jirovecii</i> pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors. <i>Blood Advances</i> , 2020, 4, 1458-1463.	2.5	28
30	MRSA colonization status as a predictor of clinical infection: A systematic review and meta-analysis. <i>Journal of Infection</i> , 2018, 77, 489-495.	1.7	27
31	Longitudinal Plasma Proteomics Analysis Reveals Novel Candidate Biomarkers in Acute COVID-19. <i>Journal of Proteome Research</i> , 2022, 21, 975-992.	1.8	27
32	The <i>Staphylococcus aureus</i> Network Adaptive Platform Trial Protocol: New Tools for an Old Foe. <i>Clinical Infectious Diseases</i> , 2022, 75, 2027-2034.	2.9	27
33	Acute Cardiac Injury in Coronavirus Disease 2019 and Other Viral Infections—A Systematic Review and Meta-Analysis. <i>Critical Care Medicine</i> , 2021, 49, 1558-1566.	0.4	26
34	Voriconazole inhibition of vitamin A metabolism: Are adverse events increased in cystic fibrosis patients?. <i>Pediatric Pulmonology</i> , 2010, 45, 661-666.	1.0	25
35	Is a Lumbar Puncture Necessary When Evaluating Febrile Infants (30 to 90 Days of Age) With an Abnormal Urinalysis?. <i>Pediatric Emergency Care</i> , 2011, 27, 1057-1061.	0.5	24
36	Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison. <i>PLoS ONE</i> , 2021, 16, e0261003.	1.1	24

#	ARTICLE	IF	CITATIONS
37	Invasive <i>Scedosporium</i> spp. and <i>Lomentospora prolificans</i> infections in pediatric patients: Analysis of 55 cases from FungiScope® and the literature. <i>International Journal of Infectious Diseases</i> , 2020, 92, 114-122.	1.5	23
38	Risk of Latent Tuberculosis Reactivation After Hematopoietic cell Transplantation. <i>Clinical Infectious Diseases</i> , 2019, 69, 869-872.	2.9	22
39	Non-invasive diagnosis of <i>Pneumocystis jirovecii</i> pneumonia: a systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2022, 28, 23-30.	2.8	22
40	Remdesivir and systemic corticosteroids for the treatment of COVID-19: A Bayesian re-analysis. <i>International Journal of Infectious Diseases</i> , 2021, 104, 671-676.	1.5	21
41	Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial. <i>Canadian Journal of Anaesthesia</i> , 2020, 67, 1201-1211.	0.7	19
42	Low-Dose TMP-SMX in the Treatment of <i>Pneumocystis jirovecii</i> Pneumonia: A Systematic Review and Meta-analysis. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa112.	0.4	19
43	Adequacy of Serial Self-performed SARS-CoV-2 Rapid Antigen Detection Testing for Longitudinal Mass Screening in the Workplace. <i>JAMA Network Open</i> , 2022, 5, e2210559.	2.8	18
44	BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2020, 4, 1881-1893.	2.5	16
45	Cell-free DNA profiling informs all major complications of hematopoietic cell transplantation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	16
46	Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for Confounding Factors. <i>CJC Open</i> , 2021, 3, 965-975.	0.7	15
47	Using MRSA Screening Tests To Predict Methicillin Resistance in <i>Staphylococcus aureus</i> Bacteremia. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 7444-7448.	1.4	14
48	Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib. <i>Leukemia and Lymphoma</i> , 2019, 60, 527-530.	0.6	14
49	A systems biology approach identifies candidate drugs to reduce mortality in severely ill patients with COVID-19. <i>Science Advances</i> , 2022, 8, .	4.7	14
50	Management of Severe Malaria in the Intensive Care Unit. <i>Critical Care Clinics</i> , 2013, 29, 865-885.	1.0	13
51	Beta-Lactam/Beta-Lactamase Inhibitor Therapy for Potential AmpC-Producing Organisms: A Systematic Review and Meta-Analysis. <i>Open Forum Infectious Diseases</i> , 2019, 6, .	0.4	13
52	Low risk of <i>Pneumocystis jirovecii</i> pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinib. <i>British Journal of Haematology</i> , 2019, 185, 788-790.	1.2	12
53	Severe Herpes Zoster Requiring Intravenous Antiviral Treatment in Allogeneic Hematopoietic Cell Transplantation Recipients on Standard Acyclovir Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1642-1647.	2.0	11
54	Comparative effectiveness of amphotericin B, azoles and echinocandins in the treatment of candidemia and invasive candidiasis: A systematic review and network meta-analysis. <i>Mycoses</i> , 2021, 64, 1098-1110.	1.8	11

#	ARTICLE	IF	CITATIONS
55	Somatic GATA2 mutations define a subgroup of myeloid malignancy patients at high risk for invasive fungal disease. <i>Blood Advances</i> , 2021, 5, 54-60.	2.5	11
56	The REinfection in COVID-19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 916-925.	1.5	11
57	Piperacillin-tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen). <i>BMJ Open</i> , 2021, 11, e040210.	0.8	10
58	Seroprevalence and Risk Factors for Severe Acute Respiratory Syndrome Coronavirus 2 Among Incarcerated Adult Men in Quebec, Canada, 2021. <i>Clinical Infectious Diseases</i> , 2022, 75, e165-e173.	2.9	10
59	Staphylococcus aureus bacteremia mortality across country income groups: A secondary analysis of a systematic review. <i>International Journal of Infectious Diseases</i> , 2022, 122, 405-411.	1.5	10
60	Increasing Rates of Penicillin Sensitivity in Staphylococcus aureus. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	9
61	Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation. <i>Blood Advances</i> , 2018, 2, 1272-1276.	2.5	9
62	Invasive Fungal Carotiditis: A Rare Manifestation of Cranial Invasive Fungal Disease: Case Series and Systematic Review of the Literature. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz392.	0.4	9
63	Use of triazoles for the treatment of invasive aspergillosis: A three-year cohort analysis. <i>Mycoses</i> , 2020, 63, 58-64.	1.8	9
64	Neither Blood Culture Positivity nor Time to Positivity Is Associated With Mortality Among Patients Presenting With Severe Manifestations of Sepsis: The FABLED Cohort Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab321.	0.4	9
65	On the Treatment of <i>Pneumocystis jirovecii</i> Pneumonia: Current Practice Based on Outdated Evidence. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab545.	0.4	9
66	SARS-CoV-2 seroprevalence in health care workers from 10 hospitals in Quebec, Canada: a cross-sectional study. <i>Cmaj</i> , 2021, 193, E1868-E1877.	0.9	9
67	What Is the Optimal Follow-up Length for Mortality in <i>Staphylococcus aureus</i> Bacteremia? Observations From a Systematic Review of Attributable Mortality. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac096.	0.4	9
68	Screening swabs surpass traditional risk factors as predictors of MRSA bacteremia. <i>BMC Infectious Diseases</i> , 2018, 18, 270.	1.3	8
69	Cytomegalovirus events in high-risk allogeneic hematopoietic cell transplantation patients who received letermovir prophylaxis. <i>Transplant Infectious Disease</i> , 2021, 23, e13619.	0.7	8
70	Daptomycin versus placebo as an adjunct to beta-lactam therapy in the treatment of <i>Staphylococcus aureus</i> bacteremia: study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 297.	0.7	7
71	Specificity of SARS-CoV-2 Antibody Detection Assays against S and N Proteins among Pre-COVID-19 Sera from Patients with Protozoan and Helminth Parasitic Infections. <i>Journal of Clinical Microbiology</i> , 2022, 60, JCM0171721.	1.8	7
72	How generalizable are randomized controlled trials (RCTs) in <i>Staphylococcus aureus</i> bacteremia? A description of the mortality gap between RCTs and observational studies. <i>Clinical Infectious Diseases</i> , 2022, , .	2.9	7

#	ARTICLE	IF	CITATIONS
73	Voice-based screening for SARS-CoV-2 exposure in cardiovascular clinics. <i>European Heart Journal Digital Health</i> , 2021, 2, 521-527.	0.7	6
74	Cross-Reacting <i>Ustilago maydis</i> Causing False-Positive Cryptococcal Antigen Test Results. <i>Journal of Clinical Microbiology</i> , 2017, 55, 3135-3137.	1.8	5
75	Predictive factors of <i>Clostridioides difficile</i> infection in hospitalized patients with new diarrhea: A retrospective cohort study. <i>PLoS ONE</i> , 2018, 13, e0207128.	1.1	5
76	Prevalence of Auto-antibodies in Pulmonary Tuberculosis. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz114.	0.4	5
77	Real-world Time to Positivity of 2 Widely Used Commercial Blood Culture Systems in Patients With Severe Manifestations of Sepsis: An Analysis of the FABLED Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa371.	0.4	5
78	Safety of Live-Attenuated Measles, Mumps, and Rubella Vaccine Administered Within 2 Years of Hematopoietic Cell Transplant. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab504.	0.4	5
79	Stability of Biological Activity of Frozen $\beta$ -lactams over Time as Assessed by Time-Lapsed Broth Microdilutions. <i>Antibiotics</i> , 2019, 8, 165.	1.5	4
80	In vitro synergy of $\beta$ -lactam combinations against KPC-producing <i>Klebsiella pneumoniae</i> strains. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3515-3520.	1.3	4
81	Hepatitis B testing practices at a tertiary care centre and their associated costs: A retrospective analysis. <i>PLoS ONE</i> , 2019, 14, e0219347.	1.1	3
82	Triazole Antifungal Susceptibility Patterns among <i>Aspergillus</i> Species in Québec, Canada. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	1.8	3
83	Reply to Singh. <i>Clinical Infectious Diseases</i> , 2020, 71, 471-472.	2.9	3
84	Using VRE screening tests to predict vancomycin resistance in enterococcal bacteremia. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, 425-429.	1.0	3
85	Kidney Transplantation in Times of Covid-19: Decision Analysis in the Canadian Context. <i>Canadian Journal of Kidney Health and Disease</i> , 2021, 8, 205435812110403.	0.6	3
86	Nosocomial mucormycosis of the thigh. <i>IDCases</i> , 2021, 25, e01225.	0.4	3
87	Organ dysfunction and death in patients admitted to hospital with COVID-19 in pandemic waves 1 to 3 in British Columbia, Ontario and Quebec, Canada: a cohort study. <i>CMAJ Open</i> , 2022, 10, E379-E389.	1.1	3
88	River otter bite in a 52-year-old woman: managing animal bites. <i>Cmaj</i> , 2016, 188, E513-E516.	0.9	2
89	Factors Associated With 30-Day Mortality Rate in Respiratory Infections Caused by <i>Streptococcus pneumoniae</i> . <i>Clinical Infectious Diseases</i> , 2018, 66, 1282-1285.	2.9	2
90	358. Comparison of Voriconazole (VORI), Isavuconazole (ISAV), and Posaconazole (POSA) in the Initial Treatment of Patients With Invasive Aspergillosis (IA). <i>Open Forum Infectious Diseases</i> , 2018, 5, S140-S141.	0.4	2

#	ARTICLE	IF	CITATIONS
91	Herpes Zoster Subunit Vaccination for Renal Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2019, 70, 718-719.	2.9	2
92	Clinical Trials Increase Off-Study Drug Use: A Segmented Time-Series Analysis. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa449.	0.4	2
93	Blood Culture Results Before and After Antimicrobial Administration. <i>Annals of Internal Medicine</i> , 2020, 172, 440.	2.0	2
94	Serodiagnostics for SARS-CoV-2. <i>Annals of Internal Medicine</i> , 2021, 174, 287-288.	2.0	2
95	Short Communication: Ongoing Impact of the Social Determinants of Health During the Second and Third Waves of the COVID-19 Pandemic in People Living with HIV Receiving Care in a Montreal-Based Tertiary Care Center. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 359-362.	0.5	2
96	Using MRSA Screening Tests to Predict Methicillin Resistance in <i>Staphylococcus aureus</i> Bacteremia. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	1
97	Efficacy of Oral Vancomycin in Preventing Recurrent <i>Clostridium difficile</i> Infection in Patients Treated With Systemic Antimicrobial Agents. <i>Clinical Infectious Diseases</i> , 2016, 63, 1391.1-1392.	2.9	1
98	The Reply. <i>American Journal of Medicine</i> , 2018, 131, e157.	0.6	1
99	2116. Comparative Effectiveness of Amphotericin B, Azoles, and Echinocandins in the Treatment of Candidemia and Invasive Candidiasis: A Systematic Review and Network Meta-Analysis. <i>Open Forum Infectious Diseases</i> , 2019, 6, S716-S716.	0.4	1
100	Assessment of Piperacillin-Tazobactam-Meropenem Synergy against Serine Carbapenemase-Producing Enterobacterales Using Time-Kill Assays. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	1
101	Handheld infrared thermometer to evaluate cellulitis: the HI-TEC study. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1814-1819.	2.8	1
102	Causing Bilateral Pneumosepsis in an Immunocompetent Adult: A Case Report and Literature Review. <i>Canadian Journal of Hospital Pharmacy</i> , 2018, 71, 208-210.	0.1	1
103	A 63-year-old man with invasive amoebiasis mimicking pulmonary tuberculosis. <i>Jammi</i> , 2017, 2, 41-45.	0.3	0
104	Reply to Dobler. <i>Clinical Infectious Diseases</i> , 2017, 65, 1423-1424.	2.9	0
105	1548. Risk of Severe Herpes Zoster (HZ) in Allogeneic Hematopoietic-Cell Transplantation (HCT) Recipients. <i>Open Forum Infectious Diseases</i> , 2018, 5, S480-S481.	0.4	0
106	1140. GATA2 Mutations Are Frequently Identified Among Patients With Myeloid Malignancies Who Develop Invasive Aspergillosis. <i>Open Forum Infectious Diseases</i> , 2018, 5, S342-S342.	0.4	0
107	1576. Risk of Clinical Tuberculosis (TB) Among Patients with Latent TB Infection (LTBI) Who Undergo Allogeneic Hematopoietic-Cell Transplantation (HCT). <i>Open Forum Infectious Diseases</i> , 2018, 5, S492-S492.	0.4	0
108	1130. Low Risk of <i>Pneumocystis jirovecii</i> Pneumonia in Patients With Waldenström's Macroglobulinemia on Ibrutinib. <i>Open Forum Infectious Diseases</i> , 2018, 5, S338-S339.	0.4	0

#	ARTICLE	IF	CITATIONS
109	2399. Î²-Lactam Therapy for Potential AmpC-Producing Organisms: A Cohort Study and an Updated Systematic Review and Meta-Analysis. <i>Open Forum Infectious Diseases</i> , 2018, 5, S716-S716.	0.4	0
110	Imported pulmonary melioidosis in QuÃ©bec, Canada. <i>Jammi</i> , 2018, 3, 108-113.	0.3	0
111	Authorsâ€™ Response. <i>Journal of Thoracic Oncology</i> , 2018, 13, e237.	0.5	0
112	Reply to Aronson et al. <i>Clinical Infectious Diseases</i> , 2020, 70, 1262.	2.9	0
113	847. The Effect of Antimicrobial Administration on Blood Culture Positivity in Patients with Severe Manifestations of Sepsis. <i>Open Forum Infectious Diseases</i> , 2019, 6, S15-S16.	0.4	0
114	2596. Invasive Fungal Disease in Patients with GATA2 Variant Hematologic Malignancy. <i>Open Forum Infectious Diseases</i> , 2019, 6, S902-S902.	0.4	0
115	Reply to Volpicelli et al. <i>Clinical Infectious Diseases</i> , 2021, 73, 168-169.	2.9	0
116	Comparison of two methods to clear the airways of critically ill children and adults with COVID-19 infection: a structured summary of a study protocol for a pilot randomized controlled trial. <i>Trials</i> , 2020, 21, 610.	0.7	0
117	A eulogy for Dr Francisco Miguel Marty Forero. <i>Transplant Infectious Disease</i> , 2021, 23, e13645.	0.7	0
118	Optimizing cost as well as yield of blood cultures in sepsis. <i>American Journal of Emergency Medicine</i> , 2021, 47, 294.	0.7	0
119	117. Adjunctive Daptomycin in the Treatment of staphylococcus Aureus Bacteremia. <i>Open Forum Infectious Diseases</i> , 2020, 7, S187-S187.	0.4	0
120	Clarithromycinâ€“Rifampin-Based Treatment for Nontuberculous Mycobacteria Infections in Immunocompromised Patients who Require Concomitant CYP-Metabolized Medications. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab582.	0.4	0